A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER)

Journal of Thoracic Oncology

Volumn 9, Issue 2, 2014, Pages 154-162

  Shi, Yuankai ^a   Au, Joseph Siu Kie ^b   Thongprasert, Sumitra ^c   Srinivasan, Sankar ^d   Tsai, Chun Ming ^e   Khoa, Mai Trong ^f   Heeroma, Karin ^g   Itoh, Yohji ^g   Cornelio, Gerardo ^h   Yang, Pan Chyr ⁱ  

^a PEKING UNION MEDICAL COLLEGE   (China)

^b QUEEN ELIZABETH HOSPITAL   (Hong Kong)

^c Faculty of Medicine Chiang Mai University   (Thailand)

^d APOLLO HOSPITALS   (India)

^e TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^f BACH MAI HOSPITAL   (Viet Nam)

^g ASTRAZENECA   (United Kingdom)

^h Hospital San Juan de Dios   (Philippines)

ⁱ NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ARTICLE; ASIAN; CANCER PATIENT; CANCER STAGING; CONTROLLED STUDY; CYTOLOGY; DEMOGRAPHY; EGFR GENE; ETHNIC GROUP; FEMALE; GENE FREQUENCY; GENE MUTATION; HISTOLOGY; HUMAN; HUMAN TISSUE; INDIA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MOLECULAR EPIDEMIOLOGY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEPTOR GENE; SMOKING; VERY ELDERLY;

ADENOCARCINOMA; ADENOCARCINOMA, BRONCHIOLO-ALVEOLAR; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ASIA; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR EPIDEMIOLOGY; MUTATION; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTOR, EPIDERMAL GROWTH FACTOR; YOUNG ADULT;

EID: 84893353535     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000033     Document Type: Article

References (34)

1. DAddario G, Frh M, Reck M, Baumann P, Klepetko W, Felip E; ESMO Guidelines Working Group. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow- up. Ann Oncol 2010;21(Suppl 5):v116-v119.
2. Crin L, Weder W, van Meerbeeck J, Felip E; ESMO Guidelines Working Group. Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21(Suppl 5):v103-v115.
3. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-957.
4. Han JY, Park K, Kim SW, et al. First-SIGNAL: first-line single-Agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol 2012;30:1122-1128.
5. Maemondo M, Inoue A, Kobayashi K, et al; North-East Japan Study Group. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-2388.
6. Mitsudomi T, Morita S, Yatabe Y, et al; West Japan Oncology Group. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11:121-128.
7. Rosell R, Carcereny E, Gervais R, et al; Spanish Lung Cancer Group in collaboration with Groupe Franais de Pneumo-Cancrologie and Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239-246.
8. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutationpositive non- small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011;12:735-742.
9. Azzoli CG, Baker S Jr, Temin S, et al; American Society of Clinical Oncology. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009;27:6251-6266.
10. DAddario G, Felip E. Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008;19 (Suppl 2):ii39-ii40.
11. National Comprehensive Cancer Network. Practice guidelines in oncology- version V.3.2012 (non-small-cell lung cancer). Available at: http://www.nccn.org/professionals/physician-gls/pdf/nscl.pdf. Accessed December 6, 2011.
12. Kawaguchi T, Matsumura A, Fukai S, et al. Japanese ethnicity compared with Caucasian ethnicity and never-smoking status are independent favorable prognostic factors for overall survival in non-small cell lung cancer: a collaborative epidemiologic study of the National Hospital Organization Study Group for Lung Cancer (NHSGLC) in Japan and a Southern California Regional Cancer Registry databases. J Thorac Oncol 2010;5:1001-1010.
13. DAngelo SP, Pietanza MC, Johnson ML, et al. Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas. J Clin Oncol 2011;29:2066-2070.
14. Rosell R, Moran T, Queralt C, et al; Spanish Lung Cancer Group. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009;361:958-967.
15. Mitsudomi T, Kosaka T, Endoh H, et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 2005;23:2513-2520.
16. Saijo N, Takeuchi M, Kunitoh H. Reasons for response differences seen in the V15-32, INTEREST and IPASS trials. Nat Rev Clin Oncol 2009;6:287-294.
17. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005;97:339-346.
18. Fukuoka M, Wu YL, Thongprasert S, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first- line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 2011;29:2866-2874.
19. Choi YL, Sun JM, Cho J, et al. EGFR mutation testing in patients with advanced non-small cell lung cancer: a comprehensive evaluation of real-world practice in an East Asian tertiary hospital. PLoS One 2013;8:e56011.
20. Sahoo R, Harini VV, Babu VC, et al. Screening for EGFR mutations in lung cancer, a report from India. Lung Cancer 2011;73:316-319.
21. Bareschino MA, Schettino C, Rossi A, et al. Treatment of advanced non small cell lung cancer. J Thorac Dis 2011;3:122-133.
22. Travis WD, Brambilla E, Noguchi M, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011;6:244-285.
23. Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004;64:8919-8923.
24. Wu YL, Zhong WZ, Li LY, et al. Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non- small cell lung cancer: a meta-Analysis based on updated individual patient data from six medical centers in mainland China. J Thorac Oncol 2007;2:430-439.
25. Sasaki H, Endo K, Konishi A, et al. EGFR Mutation status in Japanese lung cancer patients: genotyping analysis using LightCycler. Clin Cancer Res 2005;11:2924-2929.
26. Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol 2013;8:823-859.
27. Goto K, Satouchi M, Ishii G, et al. An evaluation study of EGFR mutation tests utilized for non-small-cell lung cancer in the diagnostic setting. Ann Oncol 2012;23:2914-2919.
28. Liu X, Lu Y, Zhu G, et al. The diagnostic accuracy of pleural effusion and plasma samples versus tumour tissue for detection of EGFR mutation in patients with advanced non-small cell lung cancer: comparison of methodologies. J Clin Pathol 2013;66:1065-1069.
29. Liu Y, Liu B, Li XY, et al. A comparison of ARMS and direct sequencing for EGFR mutation analysis and tyrosine kinase inhibitors treatment prediction in body fluid samples of non-small-cell lung cancer patients. J Exp Clin Cancer Res 2011;30:111.
30. Neal JW, Sequist LV. First-line use of EGFR tyrosine kinase inhibitors in patients with NSCLC containing EGFR mutations. Clin Adv Hematol Oncol 2010;8:119-126.
31. Saijo N, Fukuoka M, Thongprasert S, et al. Lung cancer working group report. Jpn J Clin Oncol 2010;40(Suppl 1):i7-i12.
32. Salto-Tellez M, Tsao MS, Shih JY, et al. Clinical and testing protocols for the analysis of epidermal growth factor receptor mutations in East Asian patients with non-small cell lung cancer: a combined clinical-molecular pathological approach. J Thorac Oncol 2011;6:1663-1669.
33. Leary AF, Castro DG, Nicholson AG, et al. Establishing an EGFR mutation screening service for non-small cell lung cancer-sample quality criteria and candidate histological predictors. Eur J Cancer 2012;48:61-67.
34. Sekine I, Yamamoto N, Nishio K, et al. Emerging ethnic differences in lung cancer therapy. Br J Cancer 2008;99:1757-1762.